Financial PerformanceCMRX reported 2Q24 results with a net loss of ($20.7MM).
Operational EfficiencyThe median duration of response decreased to 10.4 months, potentially influenced by the inclusion of four additional minor responses.
Risks And ChallengesRisks include commercial, regulatory, clinical, manufacturing, financial, liability, and intellectual challenges.